METHOD FOR THE PROGNOSIS OF SURVIVAL TIME OF A PATIENT SUFFERING FROM A SOLID CANCER
The present invention relates to an in vitro method for the prognosis of the survival time of a patient suffering from a solid cancer, comprising the quantification of the cell density of follicular B cells present in tumor-induced lymphoid structures from said patient, wherein a high density of follicular B cells indicates that the patient has a favorable prognosis and a low density of follicular B cells indicates that the patient has a poor prognosis.
1 . A method of treating a patient with a solid tumor containing tumor-induced lymphoid structures, comprising the following steps:
a) obtaining a sample of the solid tumor that contains tumor-induced lymphoid structures from the patient;
b) quantifying
within the tumor-induced lymphoid structures of the sample, a cell density of follicular B cells; and
within the whole tumor sample, a cell density of mature dendritic cells;
c) comparing the cell density of follicular B cells and the cell density of mature dendritic cells with predetermined reference values; and
d) providing the patient with chemotherapy and/or radiotherapy when the cell density of follicular B cells and the cell density of mature dendritic cells are lower than the predetermined reference values.
2 . The method of claim 1 , wherein the solid tumor is a lung cancer tumor, a colorectal cancer tumor or a breast cancer tumor.
3 . The method of claim 2 wherein the lung cancer tumor is a non-small cell lung cancer tumor.
4 . The method of claim 1 wherein the patient is a patient with an early stage of cancer.
5 . The method of claim 4 wherein the patient did not receive neo-adjuvant or adjuvant therapy.
6 . The method of claim 1 wherein the patient is a patient with an advanced stage of cancer.
7 . The method of claim 6 wherein, the patient has received adjuvant therapy.
8 . The method of claim 1 wherein said step of quantifying is performed by immunohistochemistry with an anti-CD20 and anti-CD208 antibodies.